POSITION PAPER

Delegation: Cyprus
Committee: World Health Organization
Topic Area B: Reforming the Global Pharmaceutical Industry

A very rapid development in recent years in the pharmaceutical industry can indeed
be felt all around the world. This is understandable, given how important the role of the
industry in dealing with various issues such as health care quality, which would affect all
other industries as health becomes solid in the execution of all jobs in the world. Then, the
problem that arises is, this is a time of relative uncertainty for many pharmaceutical
companies operating in the world. The industry has many concerns about issues related to
data exclusivity, registration of generic drugs with the Food & Drug Administration (FDA),
outright counterfeiting of medicinal products and possible compulsory licensing of patented
life-saving drugs by the Government Pharmaceutical Organization (GPO). The primary
source of uncertainties that exist relate to so called “data exclusivity” of trade secret
information, which an R&D based drug manufacturer may have on file with the FDA. This is
what we believe need to be emphasized to the world, that uncertainty is what causes this
industry is difficult to develop. It takes one clear rules to regulate these things, so that the
pharmaceutical industry can continue to evolve to meet the needs of the world community.

Regarding to this concerning issues about the importance of pharmaceutical

industries, mostly in how developed countries which is also act as the supplier for these
medication can emplace its position in world degree. Cyprus has done some actions before,
these actions done to balance the needs of the medication and the needs of contra R&D cost
that has been expenditure. These things are; the open invitation and negotiation procedure in
the public sector, as well as the on - patent originators, off-patent originators, and generics in
the private sector. These recommendations constitute temporary solutions that always been
reviewed once the country’s economic situation improves. Open invitation and negotiations
are done by urge developing countries to get involved in R&D process. So they indirectly
know the steps on how to develop this medication. On – patent, off – patent, and generic
medication is done by shortening the number of patent years of medication, this steps done by
considering how much world needs its medicine.

As the reforms came on line, demand for healthcare in many countries, we urged
standardization by all countries in the world relating to the use of the pharmaceutical
industry, which is useful to resolve the debate about the misunderstanding of the current
issue. Also we propose our past action that has been done before. It was the open invitation
and negotiation procedure. It is believed that by this way we can open the gate for developing
and underdeveloped countries to get easier access to newly developed medication, without
just giving it to them freely. It will also decrease their country dependence, so we hope
someday they can develop their own. We also should reconsider the years applied for
medicine patent. We should see the world’s dependence on this medication on defining the
numbers of years in contract. Last but not least, Cyprus giving concern to the safety of the
pharmaceutical product testing. We sees that industry needs to reconsider the objects of
testing the newly produce pharmaceutical products. The aim is to set the effectively for the
medicine, so it can really useful to use, and we can make sure it doesn’t have much side
effects.